Causes of death after transjugular intrahepatic portosystemic shunt in patients with hepatic sinusoidal obstruction syndrome
-
摘要:
目的分析肝窦阻塞综合征(HSOS)患者行经颈静脉肝内门体分流术(TIPS)后死亡的临床特点及原因,探讨进一步提高此类患者生存率的防治措施。方法回顾性分析2013年1月-2019年12月南京鼓楼医院收治的HSOS患者293例,其中行TIPS治疗后死亡20例,统计并分析20例患者的一般资料、实验室检查及临床治疗方案,比较病程不同阶段的指标变化及出现并发症等情况。正态分布的计量资料术前术后比较采用配对t检验;非正态分布的计量资料术前术后比较采用Wilcoxon秩和检验。结果20例死亡患者的平均生存时间为(15. 15±4. 21)周。其中男15例,女5例,平均年龄(67. 60±7. 01)岁,≥60岁患者17例(85%),90%以上的患者有腹胀、少尿等临床表现。9例(45%)合并慢性基础疾病,5例(25%)合并两种以上基础疾病。总体上,门静脉压力由术前的(21. 67±5. 15) mm Hg下降至术后的(8. 17±4. 98) mm Hg(t=10. 318,P<0. 05)。患者术前TBil、DBil、D-二聚体水平均明显高于正常值,术后5 d上述指标较术前仍有明显升高(Z值...
-
关键词:
- 肝静脉闭塞性疾病 /
- 门体分流术,经颈静脉肝内 /
- 死亡原因
Abstract:Objective To investigate the clinical features and causes of death after transjugular intrahepatic portosystemic shunt( TIPS) in patients with hepatic sinus obstruction syndrome( HSOS),as well as the prevention and treatment measures to further improve the survival rate of such patients. Methods A retrospective analysis was performed for 293 patients with HSOS who were admitted to Nanjing Drum Tower Hospital from January 2013 to December 2019,among whom 20 patients died after TIPS. General information,laboratory examination,and clinical treatment regimen were analyzed,and clinical indices and complications were compared at different stages of the disease.The paired t-test was used for comparison of normally distributed continuous data between groups,and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups. Results The mean survival time was 15. 15 ± 4. 21 weeks for the 20 patients who died,among whom there were 15 male patients and 5 female patients,with a mean age of 67. 60 ± 7. 01 years;there were 17 patients( 85%) aged ≥60 years,and more than 90% of the patients had abdominal distention and oliguria. Among the 20 patients who died,9( 45%) had chronic underlying diseases,and 5( 25%) had more than two underlying diseases. Portal venous pressure decreased from 21. 67 ± 5. 15 mm Hg before surgery to 8. 17 ± 4. 98 mm Hg after surgery( t = 10. 318,P < 0. 05). The levels of total bilirubin,direct bilirubin,and D-dimer were significantly higher than the normal values before surgery,and there were significant increases in these levels on day 5 after surgery( Z = 3. 823,3. 823,2. 756,all P < 0. 05); the hemoglobin level,platelet count,and creatinine level tended to decrease on day 5 after surgery( t = 4. 979,t = 2. 147,Z =-3. 125,all P < 0. 05). Three patients had hepatic encephalopathy before surgery,while 10 patients( 50%) had hepatic encephalopathy after surgery. Causes of death included acute liver failure,infectious shock,and multiple organ failure syndrome( MODS). Conclusion The possible risk factors for death after TIPS in HSOS patients include underly-ing diseases,high bilirubin,and complications such as hepatic encephalopathy and renal dysfunction. Causes of death mainly include acute liver failure and MODS. Ultrasound and laboratory markers should be reexamined during anticoagulation therapy to identify the patients with progression to severe diseases as early as possible,and in case of progressive deterioration of indices,TIPS should be selected as early as possible to improve the survival rate and prognosis of such patients. In addition,hemobilia should be observed during and after surgery,and intervention measures should be adopted in time to further reduce mortality rate.
-
[1] ZHUGE Y,LIU Y,XIE W,et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol,2019,34(4):634-642. [2] YANG XQ,YE J,LI X,et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:Pathogenesis,clinical manifestations,diagnosis,treatment,and outcomes[J].World J Gastroenterol,2019,25(28):3753-3763. [3] DELEVE LD,SHULMAN HM,McDONALD GB. Toxic injury to hepatic sinusoids:Sinusoidal obstruction syndrome(veno-occlusive disease)[J]. Semin Liver Dis,2002,22(1):27-42. [4] Cooperative Group for Hepatic and Gall Diseases,Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome(2017,Nanjing)[J]. J Clin Hepatol,2017,33(9):1627-1637.(in Chinese)中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J].临床肝胆病杂志,2017,33(9):1627-1637. [5] BOYER TD. Transjugular intrahepatic portosystemic shunt:Current status[J]. Gastroenterology,2003,124(6):1700-1710. [6] LIU ZL,FAN ZP,GOU YS,et al. Clinical features,pathogenesis,and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol,2019,35(1):208-212.(in Chinese)刘贞利,范作鹏,勾钰淞,等.不同类型肝窦阻塞综合征的临床特征、发病机制与诊治[J].临床肝胆病杂志,2019,35(1):208-212. [7] ROEKER LE,KIM HT,GLOTZBECKER B,et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation[J]. Biol Blood Marrow Transplant,2019,25(1):137-144. [8] GAO H,LI N,WANG JY,et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids[J]. J Dig Dis,2012,13(1):33-39. [9] CRAWFORD MJ. Vascular disorders of the liver[J]. Clin Liver Dis,2010,14(4):635-650. [10] LIN G,WANG JY,LI N,et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol,2011,54(4):666-673. [11] ZHUGE YZ,WANG Y,ZHANG F,et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int,2018,38(10):1867-1874. [12] CHOJKIER M. Hepatic sinusoidal-obstruction syndrome:Toxicity of pyrrolizidine alkaloids[J]. J Hepatol,2003,39(3):437-446. [13] CORBACIOGLU S,CESARO S,FARACI M,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation:An open-label,phase 3,randomised controlled trial[J]. Lancet,2012,379(9823):1301-1309. [14] PENG C,ZHANG X,ZHANG F,et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:A retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol,2020,32(9):1168-1178. [15] WANG Y,QIAO D,LI Y,et al. Risk factors for hepatic venoocclusive disease caused by Gynura segetum:A retrospective study[J]. BMC Gastroenterol,2018,18(1):156.
计量
- 文章访问数: 4394
- HTML全文浏览量: 42
- PDF下载量: 84
- 被引次数: 0